Gemini Bio Revenue and Competitors

Since its inception in 1985, Gemini Bio’s focus and niche has always been to produce consistent, high quality products, coupled with exceptional, personalized service. The company began operations in Calabasas, California, with marketing activities targeting the research and biotech community across the state. As a result of continued and progressive success, Gemini consistently expanded the sales force to be able to service the entire United States. Today, Gemini is a leading manufacturer and supplier of cell culture media, sera, and other reagents to the scientific community across academic research and the biotechnology, cell and gene therapy, and biopharma industries. A national sales force and an international distribution network serves cell culture laboratories worldwide. In September 2018, BelHealth Investment Partners, a healthcare private equity firm, invested in Gemini Bio. A new leadership team led by CEO Dale Gordon was brought on to guide the company through its exciting next chapter. With this growth investment, Gemini moved into a new state-of-the-art 25,000 square foot facility in West Sacramento in 2020. Throughout its growth, Gemini has maintained the personalized service on which its reputation was built. Samples and orders are often processed and shipped the same day they are requested, enabling customers to receive their orders the very next day. Gemini’s sales team visits customers regularly to provide mutually agreed solutions to customer needs. Today, we are proud of what we uniquely offer at Gemini: competitively priced products, extensively tested and proven to be of high quality over the last 35 years, combined with exceedingly unbeatable service within the industry.